Barclays PLC Purchases 17,101 Shares of Liquidia Co. (NASDAQ:LQDA)

Barclays PLC increased its stake in shares of Liquidia Co. (NASDAQ:LQDA - Free Report) by 17.1% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 117,085 shares of the company's stock after purchasing an additional 17,101 shares during the period. Barclays PLC owned 0.14% of Liquidia worth $1,377,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in LQDA. Vanguard Group Inc. lifted its holdings in shares of Liquidia by 3.4% in the fourth quarter. Vanguard Group Inc. now owns 3,557,296 shares of the company's stock worth $41,834,000 after buying an additional 115,367 shares in the last quarter. LM Advisors LLC bought a new position in Liquidia in the 4th quarter valued at $25,948,000. Geode Capital Management LLC grew its position in shares of Liquidia by 8.2% during the 4th quarter. Geode Capital Management LLC now owns 1,339,254 shares of the company's stock valued at $15,753,000 after purchasing an additional 101,597 shares in the last quarter. Invesco Ltd. increased its holdings in shares of Liquidia by 2,675.0% in the fourth quarter. Invesco Ltd. now owns 700,171 shares of the company's stock worth $8,234,000 after purchasing an additional 674,940 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Liquidia by 9.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 428,570 shares of the company's stock worth $5,040,000 after purchasing an additional 38,313 shares during the period. Institutional investors own 64.54% of the company's stock.

Insider Activity

In other Liquidia news, insider Rajeev Saggar sold 2,450 shares of Liquidia stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $13.67, for a total value of $33,491.50. Following the transaction, the insider now directly owns 263,152 shares of the company's stock, valued at $3,597,287.84. The trade was a 0.92 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Roger Jeffs sold 14,130 shares of the stock in a transaction that occurred on Monday, April 14th. The shares were sold at an average price of $13.57, for a total value of $191,744.10. Following the sale, the chief executive officer now directly owns 1,006,420 shares of the company's stock, valued at approximately $13,657,119.40. This trade represents a 1.38 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 33,138 shares of company stock valued at $450,233. Insiders own 30.10% of the company's stock.

Liquidia Trading Down 3.4 %

Shares of LQDA stock traded down $0.55 during trading hours on Tuesday, hitting $15.57. 1,343,841 shares of the company's stock were exchanged, compared to its average volume of 997,067. The company has a market capitalization of $1.33 billion, a PE ratio of -9.55 and a beta of 0.24. Liquidia Co. has a 12-month low of $8.26 and a 12-month high of $16.81. The business's 50 day simple moving average is $14.23 and its 200-day simple moving average is $13.06.

Liquidia (NASDAQ:LQDA - Get Free Report) last issued its earnings results on Wednesday, March 19th. The company reported ($0.46) EPS for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.08). Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%. The business had revenue of $2.92 million during the quarter, compared to analysts' expectations of $4.60 million. Equities analysts anticipate that Liquidia Co. will post -1.51 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on LQDA shares. Needham & Company LLC restated a "buy" rating and set a $25.00 target price on shares of Liquidia in a research report on Thursday, April 10th. Scotiabank boosted their price objective on Liquidia from $34.00 to $36.00 and gave the stock a "sector outperform" rating in a report on Monday. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $29.00 target price on shares of Liquidia in a research note on Thursday, March 20th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, Liquidia currently has a consensus rating of "Buy" and an average target price of $26.88.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).